Evidence map›Paper›PMID 27280291›Full record

ArticlePloS one2016

Pharmacokinetic-Pharmacodynamic Analysis on Inflammation Rat Model after Oral Administration of Huang Lian Jie Du Decoction.

Wei Ren, Ran Zuo, Yao-Nan Wang, Hong-Jie Wang, Jian Yang, Shao-Kun Xin, Ling-Yu Han, Hai-Yu Zhao, Shu-Yan Han, Bo Gao and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Wei RenInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Ran ZuoLi Kang Hospital, Beijing 102609, People's Republic of China.
Yao-Nan WangCapital Medical University, Beijing 100069, China.
Hong-Jie WangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Jian YangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Shao-Kun XinInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Ling-Yu HanInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Hai-Yu ZhaoInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Shu-Yan HanKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integration of Chinese and WesternMedicine, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, PR China.
Bo GaoAnhui Jinchan Biochemistry Company Ltd., Huaibei 235000, China.
Hao HuState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China.
Yuan-Jia HuState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China.
Bao-Lin BianInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Nan SiInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNCapital Medical University · CNUniversity of Macau · MOHuaibei Mining (China) · CNPeking University Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huang-Lian-Jie-Du Decoction (HLJDD) is a classical Traditional Chinese Medicine (TCM) formula with heat-dissipating and detoxifying effects. It is used to treat inflammation-associated diseases. However, no systematic pharmacokinetic (PK) and pharmacodynamic (PD) data concerning the activity of HLJDD under inflammatory conditions is available to date. In the present study, the concentration-time profiles and the hepatic clearance rates (HCR) of 41 major components in rat plasma in response to the oral administration of a clinical dose of HLJDD were investigated by LC-QqQ-MS using a dynamic multiple reaction monitoring (DMRM) method. Additionally, the levels of 7 cytokines (CKs) in the plasma and the body temperature of rats were analyzed. Furthermore, a PK-PD model was established to describe the time course of the hemodynamic and anti-inflammatory effects of HLJDD. As one of the three major active constituents in HLJDD, iridoids were absorbed and eliminated more easily and quickly than alkaloids and flavonoids. Compared with the normal controls, the flavonoids, alkaloids and iridoids in inflamed rats exhibited consistently changing trends of PK behaviors, such as higher bioavailability, slower elimination, delays in reaching the maximum concentration (Tmax) and longer substantivity. The HCR of iridoids was different from that of alkaloids and flavonoids in inflamed rats. Furthermore, excellent pharmacodynamic effects of HLJDD were observed in inflamed rats. The levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-1β, IL-10, and macrophage inflammatory protein-2 (MIP-2) and body temperature significantly decreased after the administration of HLJDD. Based on PK-PD modeling with the three-phase synchronous characterization of time-concentration-effect, flavonoids exhibited one mechanism of action in the anti-inflammatory process, while iridoids and alkaloids showed another mechanism of action. Taken together, the results demonstrated that HLJDD may restrain inflammation synergistically via its major constituents (alkaloids, flavonoids and iridoids). A correlation between the exposure concentration of different types of compounds and their anti-inflammatory effects in the body was shown. This study provides a comprehensive understanding of the anti-inflammatory activity of HLJDD.

Indexed as

Administration, OralAnimalsAnti-Inflammatory Agents, Non-SteroidalChromatography, LiquidCytokinesDrugs, Chinese HerbalInflammationMaleMass SpectrometryRatsRats, Sprague-DawleyAnti-Inflammatory Agents, Non-SteroidalCytokinesDrugs, Chinese Herbaloren gedoku to

Identifiers

PMID27280291
PMCPMC4900566
OpenAlexW2414981403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.